您的当前位置:首页 > 行业数据 > 宜明昂科-B2020年至2024年营业收入情况(单位:人民币百万元)
图片属性
图片格式:PNG 图片大小:89KB 图片尺寸:1724*974
同报告图片
 / 4
宜明昂科-B2020年至2024年营业收入情况(单位:人民币百万元)_第1页
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
宜明昂科-B2020年至2024年营业收入情况(单位:人民币百万元)_第2页
宜明昂科-B2020年至2024年营业收入情况(单位:人民币百万元)_第3页
宜明昂科-B2020年至2024年营业收入情况(单位:人民币百万元)_第4页
宜明昂科-B2020年至2024年营业收入情况(单位:人民币百万元)_第5页
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
所属报告: 宜明昂科~B-港股公司研究报告-CD47融合蛋白安全性及疗效优秀市场空间广阔-250512(22页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠